Efgartigimod for the Treatment of Acute Optic Neuritis
Efgartigimod for the Treatment of Acute Optic Neuritis
Recruiting · NCT06453694 · Registry updated 2025-11-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efgartigimod for the Treatment of Acute Optic Neuritis | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, multiple sclerosis, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 2 | 2025-11-10 | NCT06453694 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Anastasia Vishnevetsky, MD, MPH | 1 |
| argenx | 52 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts Eye and Ear Infirmary | Boston | United States | 18 |
| Massachusetts General Hospital | Boston | United States | 1015 |